急性膵炎の市場規模、シェア、成長分析：診断別、原因別、治療別、エンドユーザー別、地域別 - 産業予測 2025～2032年

急性膵炎の世界市場規模は2023年に58億米ドルとなり、予測期間（2025-2032年）のCAGRは5.9%で、2024年の61億4,000万米ドルから2032年には97億2,000万米ドルに成長する見通しです。

世界の急性膵炎市場は、症例数の増加と医療の著しい進歩に後押しされ、急速に進化しています。重篤な膵炎は深刻な健康リスクをもたらすため、効果的な診断、治療、管理ソリューションに対する需要が高まっています。主な市場促進要因としては、肥満、飲酒、胆石などの危険因子に起因する有病率の増加、診断技術の向上、新規治療オプションなどが挙げられます。この分野は競争が激しく、製薬企業、医療機器メーカー、ヘルスケアプロバイダーは、研究、臨床試験、戦略的提携に積極的に取り組み、製品の充実を図っています。継続的なイノベーションとコラボレーションが市場の将来を形成し、患者の転帰を改善し、この重大な健康状態に関連する複雑性に対処することを目指すと予想されます。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• ケーススタディ
• 技術の進歩

急性膵炎市場規模：診断別& CAGR（2025-2032）

• 市場概要
• 画像検査
• 臨床検査

急性膵炎市場規模：原因別& CAGR（2025-2032）

• 市場概要
• 胆石
• アルコール
• その他

急性膵炎市場規模：治療別& CAGR（2025-2032）

• 市場概要
• 点滴
• 栄養補給
• 鎮痛剤
• 内視鏡的逆行性胆道膵管造影検査（ERCP）
• その他

急性膵炎市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院
• クリニック
• 診断センター
• その他

急性膵炎市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Pfizer Inc.（United States）
• Merck & Co., Inc.（United States）
• Baxter International Inc.（United States）
• Abbott Laboratories（United States）
• B. Braun SE（Germany）
• CalciMedica Inc.（United States）
• Dynavax Technologies Corporation（United States）
• Fresenius SE & Co. KGaA（Germany）
• GlaxoSmithKline plc（United Kingdom）
• Olympus Corporation（Japan）
• SCM Lifescience（South Korea）
• Samsung Bioepis（South Korea）
• GNT Pharma Co.（South Korea）
• Medtronic plc（Ireland）
• Boston Scientific Corporation（United States）
• Takeda Pharmaceuticals（Japan）
• Novartis AG（Switzerland）
• AbbVie Inc.（United States）
• General Electric Company（United States）
• Mitsubishi Tanabe Pharma Corporation（Japan）

結論と推奨事項

Global Acute Pancreatitis Market size was valued at USD 5.8 billion in 2023 and is poised to grow from USD 6.14 billion in 2024 to USD 9.72 billion by 2032, growing at a CAGR of 5.9% during the forecast period (2025-2032).

The global acute pancreatitis market is evolving rapidly, fueled by rising case numbers and significant medical advancements. This severe pancreatic inflammation poses serious health risks, resulting in a growing demand for effective diagnosis, treatment, and management solutions. Key market drivers include increased prevalence attributed to risk factors like obesity, alcohol consumption, and gallstones, alongside improvements in diagnostic technologies and novel therapeutic options. The sector is highly competitive, with pharmaceutical firms, medical device manufacturers, and healthcare providers actively engaged in research, clinical trials, and strategic alliances to enhance their offerings. Continuous innovation and collaboration are anticipated to shape the market's future, aiming to improve patient outcomes and address the complexities associated with this critical health condition.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Acute Pancreatitis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Acute Pancreatitis Market Segmental Analysis

Global Acute Pancreatitis Market is segmented by Diagnosis, Cause, Treatment, End user and region. Based on Diagnosis, the market is segmented into Imaging Tests and Laboratory Tests. Based on Cause, the market is segmented into Gallstones, Alcohol and Others. Based on Treatment, the market is segmented into Intravenous fluid, Nutritional support, Analgesics, Endoscopic Retrograde Cholangiopancreatography (ERCP) and Others. Based on End user, the market is segmented into Hospitals, Clinics, Diagnostic Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Acute Pancreatitis Market

The Global Acute Pancreatitis market is expected to experience significant growth driven by the rising prevalence of diabetes, which can be exacerbated by pancreatitis as it damages insulin-producing cells in the pancreas. Approximately 45% of individuals with chronic pancreatitis eventually develop diabetes, highlighting a crucial link between these conditions. Furthermore, the market is supported by an aging population and proactive government initiatives aimed at enhancing awareness and education regarding pancreatic health. Additionally, changing consumer lifestyles, increasing obesity rates, and the potential rise in pancreatic cancer cases will further contribute to the expansion of the Acute Pancreatitis market.

Restraints in the Global Acute Pancreatitis Market

The Global Acute Pancreatitis market faces several significant restraints that may hinder its growth. One of the primary challenges is the high cost associated with treatment, which can limit accessibility for patients. Furthermore, developing economies may struggle with inadequate healthcare infrastructure, complicating treatment access and reducing market expansion potential. Additionally, a stringent regulatory environment adds another layer of complexity, while poor reimbursement practices deter patients from seeking necessary care. Lastly, a lack of public awareness about Acute Pancreatitis further stifles market growth, as it reduces the urgency for innovative treatments and interventions. These factors collectively contribute to a slow market development trajectory.

Market Trends of the Global Acute Pancreatitis Market

The global acute pancreatitis market is currently experiencing notable trends that emphasize early diagnosis and personalized treatment strategies. Increased investment in advanced diagnostic technologies aims to facilitate the swift identification of acute pancreatitis, allowing for timely therapeutic intervention and reduced complication rates. Furthermore, there is a rising inclination towards precision medicine, driven by advancements in genetic profiling and molecular diagnostics that allow for customized treatment plans. Additionally, the integration of digital health solutions is revolutionizing patient management and monitoring. Collectively, these trends are driving innovation in therapies, improving patient outcomes, and enhancing overall care in the acute pancreatitis landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Acute Pancreatitis Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Imaging Tests
• Laboratory Tests

Global Acute Pancreatitis Market Size by Cause & CAGR (2025-2032)

• Market Overview
• Gallstones
• Alcohol
• Others

Global Acute Pancreatitis Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Intravenous fluid
• Nutritional support
• Analgesics
• Endoscopic Retrograde Cholangiopancreatography (ERCP)
• Others

Global Acute Pancreatitis Market Size by End user & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Diagnostic Centers
• Others

Global Acute Pancreatitis Market Size & CAGR (2025-2032)

• North America (Diagnosis, Cause, Treatment, End user)
  • US
  • Canada
• Europe (Diagnosis, Cause, Treatment, End user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis, Cause, Treatment, End user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis, Cause, Treatment, End user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis, Cause, Treatment, End user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B. Braun SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CalciMedica Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dynavax Technologies Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius SE & Co. KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Olympus Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SCM Lifescience (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GNT Pharma Co. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceuticals (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• General Electric Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Tanabe Pharma Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations